Also Known As: Eliquis, Apixaban
Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.
Apixaban is a factor Xa inhibitor (anticoagulant) indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.  A systematic review of new anticoagulants states the treatment benefits of apixaban and other new anticoagulants compared with warfarin are small and vary depending on the control achieved by warfarin treatment. Patients already taking warfarin with excellent international normalized ratio (INR) control may have little to gain by switching to new oral anticoagulants in atrial fibrillation.
In Europe, apixaban is sometimes used to prevent the formation of blood clots in the veins (deep venous thrombosis) in adults who have had an operation to replace a hip or knee. In a systematic review of new oral anticoagulants (Noacs) against low-molecular-weight heparin (LMWH) there is marginal clinical benefit over LMWH and it is offset by increased risk for major bleeding. New oral anticoagulants have not been compared with warfarin.
Apixaban is not indicated for prosthetic heart valves or for mitral stenosis.